CLAIMS

What is claimed as new and desired to be protected by Letters Patent of the United States is:

1. A polyamine having the structure



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof, and wherein said polyamine is a non-symmetrical xylene.

2. A polyamine having the structure



wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocytl, N-methyl-2-aminoethyl, N-methyl-3-

aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocytyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;

R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen, or fluorine;

and halogenated forms thereof, and wherein said polyamine is a non-symmetrical derivative of xylene.

3. A polyamine having the structure



wherein, m and n can be 0 to 7 independently, but m cannot equal n when R_1 equals R_2 and R_3 equals R_4, o can be 2 to 4, R can be independently selected from H, $-CH_3$ or $-CH_2CH_3$, R_1 and R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine, and wherein said polyamine is a non-symmetrical xylene.

4. A polyamine having the structure



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m and n can be 0 to 7 independently and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine.

5. A polyamine having the structure



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m can be 0 to 7, n can be 0 to 8 and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine.

6. The polyamine of any one of claims 1-5 wherein said structure is that of compounds A-Q, T and U as shown in Figure 1.

7. A pharmaceutical composition useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable, comprising a polyamine according to any one of claims 1-6 and a pharmaceutically acceptable excipient, diluent or vehicle.

8. The composition of claim 7 wherein said excipient, diluent or vehicle is pharmaceutically or cosmetically acceptable.

9. The composition of claim 7 wherein said excipient, diluent or vehicle is for topical or intra-aural administration.

10. The composition of claim 7 formulated for intravenous, subcutaneous, intramuscular, intracranial, intraperitoneal, topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural, rectal, or parenteral administration.

11. A method of treating one or more conditions associated with cellular proliferation comprising administration of a polyamine represented by at least one of the following structures:



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;



wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocytl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocytyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the

aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;

R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen, or fluorine;

and halogenated forms thereof;



wherein, m and n can be 0 to 7 independently, but m cannot equal n when R_1 equals R_2 and R_3 equals R_4, o can be 2 to 4, R can be independently selected from H, $-CH_3$ or $-CH_2CH_3$, R_1 and R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine;



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m and n can be 0 to 7 independently and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine; and



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m can be 0 to 7, n can be 0 to 8 and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine.

12. The method of claim 11 wherein said administration is systemic.

13. The method of claim 11 wherein said administration is oral.

14. The method of claim 11 wherein said administration is via a time-release vehicle.

15. A method of inhibiting hair growth comprising topical administration to a subject in need of hair growth inhibition of a polyamine represented by at least one of the following structures:



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;



wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-

aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocytl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocytyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;

R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen, or fluorine;

and halogenated forms thereof;



wherein, m and n can be 0 to 7 independently, but m cannot equal n when R_1 equals R_2 and R_3 equals R_4, o can be 2 to 4, R can be independently selected from H, $-CH_3$ or $-CH_2CH_3$, R_1 and R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine;



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m and n can be 0 to 7 independently and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine; and



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m can be 0 to 7, n can be 0 to 8 and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine.

16. The method of claim 15 wherein polyamine is formulated as a cosmetic.

17. A method of inhibiting hair loss (alopecia) comprising topical administration of a subject undergoing radiation or chemotherapy a polyamine represented by at lest one of the following structures:



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;



wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen –CH_3, -CH_2CH_3, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocytl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocytyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;

R_2 can be independently selected from hydrogen, -CH_3 or –CH_2CH_3 and R_3 and R_4 may be the same or different and are independently selected from hydrogen, or fluorine;

and halogenated forms thereof;



wherein, m and n can be 0 to 7 independently, but m cannot equal n when R_1 equals R_2 and R_3 equals R_4, o can be 2 to 4, R can be independently selected from H, -CH_3 or -CH_2CH_3, R_1 and R_2 can be independently selected from hydrogen, -CH_3 or -CH_2CH_3 and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine;



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m and n can be 0 to 7 independently and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine; and



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m can be 0 to 7, n can be 0 to 8 and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine.

18. A method of treating fungal, bacterial, viral and parasitic agents, comprising administration of a polyamine represented by at least one of the following structures:



wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring

aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;



wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen $-CH_3$, $-CH_2CH_3$, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocytl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminocytyl and R_1 is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic substituted aliphatic; an aliphatic-substituted aromatic; and halogenated forms thereof;

R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen, or fluorine;

and halogenated forms thereof;



wherein, m and n can be 0 to 7 independently, but m cannot equal n when R_1 equals R_2 and R_3 equals R_4, o can be 2 to 4, R can be independently selected from H, $-CH_3$ or $-CH_2CH_3$, R_1 and R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine;



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m and n can be 0 to 7 independently and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine; and



wherein, R is hydrogen, $-CH_3$, or $-CH_2CH_3$, m can be 0 to 7, n can be 0 to 8 and o can be 2 to 4, R_2 can be independently selected from hydrogen, $-CH_3$ or $-CH_2CH_3$ and R_3 and R_4 may be the same or different and are independently selected from hydrogen or fluorine.

19. A method according to claim 11 wherein said condition is selected from the group consisting of cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease and other inflammatory bowel diseases.

20. A method of treating one or more conditions associated with cellular proliferation comprising administration of at least one of B, T or U shown in Figure 1.

21. The method of claim 20 wherein said administration is systemic.

22. The method of claim 20 or 21 wherein said administration is oral.

23. The method of claim 20 or 21 wherein said administration is via a time-release vehicle.

24. A method of inhibiting hair growth comprising topical administration of at least one of B, T or U shown in Figure 1 to a subject in need of hair growth inhibition.

25. The method of claim 20 wherein said B, T or U is formulated as a cosmetic.

26. A method of inhibiting hair loss (alopecia) comprising topical administration of at least one of B, T or U shown in Figure 1 to a subject undergoing radiation or chemotherapy.

27. A method of treating a member selected from the group consisting of fungal, bacterial, viral and parasitic agents, comprising administration of at least one of B, T or U shown in Figure 1.

28. A method according to claim 20 wherein said condition is selected from the group consisting of cancer, mucositis, asthma, inflammation, autoimmune disease, psoriasis, restentosis, rheumatoid arthritis, scleroderma, systemic and cutaneous lupus erythematosus, Type I insulin dependent diabetes, tissue transplantation, osteoporosis, hyperparathyroidism, treatment of peptic ulcer, glaucoma, Alzheimer's disease, Crohn's disease and inflammatory bowel diseases.

29. The polyamine of claim 1 wherein said structure is that of compound Q as shown in Figure 1.

30. The polyamine of claim 1 wherein said structure is that of compound B as shown in Figure 1.

31. The polyamine of claim 1 wherein said structure is that of compound M as shown in Figure 1.

32. The polyamine of claim 1 wherein said structure T as shown in Figure 1.

33. The polyamine of claim 1 wherein said structure U as shown in Figure 1.

5